Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
暂无分享,去创建一个
K. O'Byrne | A. Baird | K. Gately | M. Barr | P. Godwin | A. M. Baird | S. Heavey | M. P. Barr | K. J. O’Byrne | K. Gately | S. Heavey | P. Godwin
[1] Y. Nakamura,et al. NF-κB activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage , 2007, Oncogene.
[2] Funda Meric-Bernstam,et al. Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Vousden,et al. Role of NF-kappaB in p53-mediated programmed cell death. , 2000, Nature.
[4] W. Kolch,et al. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells , 2008, Oncogene.
[5] Peng Huang,et al. Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-κB* , 2004, Journal of Biological Chemistry.
[6] S. Miyamoto. RelA life and death decisions. , 2004, Molecular cell.
[7] G. Linette,et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma , 2010, Cancer.
[8] Y. Ishigatsubo,et al. Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. , 2010, Lung cancer.
[9] Ying Jin,et al. Smac3, a Novel Smac/DIABLO Splicing Variant, Attenuates the Stability and Apoptosis-inhibiting Activity of X-linked Inhibitor of Apoptosis Protein* , 2003, Journal of Biological Chemistry.
[10] T. Waldmann,et al. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. , 2002, Cancer research.
[11] D. Esseltine,et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] L. Nelles,et al. Activation of NF-κB by Akt upregulates Snail expression and induces epithelium mesenchyme transition , 2007, Oncogene.
[13] H. Hansen,et al. Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.
[14] William Arbuthnot Sir Lane,et al. NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. , 2002, Nature cell biology.
[15] G. Xiao,et al. NF-κB Signaling Pathway Governs TRAIL Gene Expression and Human T-cell Leukemia Virus-I Tax-induced T-cell Death* , 2001, The Journal of Biological Chemistry.
[16] J. Tschopp,et al. NF-κB Signals Induce the Expression of c-FLIP , 2001, Molecular and Cellular Biology.
[17] S. Chaney,et al. Protein interactions with platinum-DNA adducts: from structure to function. , 2004, Journal of inorganic biochemistry.
[18] N. Perkins,et al. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. , 2004, Molecular cell.
[19] S. Miyamoto,et al. Induction of a pro‐apoptotic ATM–NF‐κB pathway and its repression by ATR in response to replication stress , 2008, The EMBO journal.
[20] Katherine S. Lovejoy,et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. , 2010, Genes & development.
[21] Inder M Verma,et al. NF-kappaB regulation in the immune system. , 2002, Nature reviews. Immunology.
[22] G. Bar-Sela,et al. Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer , 2010, Nutrition and Cancer.
[23] Shadan Ali,et al. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. , 2005, Cancer research.
[24] D. Feldser,et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.
[25] C. Iadecola,et al. cis-Acting Element-specific Transcriptional Activity of Differentially Phosphorylated Nuclear Factor-κB* , 2005, Journal of Biological Chemistry.
[26] J. Schmid,et al. BMS-345541 Targets Inhibitor of κB Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor κB and Mitochondria Pathways , 2006, Clinical Cancer Research.
[27] Hua Yu,et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.
[28] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[29] Steven J. Tucker,et al. Elevated NF-κB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis , 2007, Proceedings of the National Academy of Sciences.
[30] S. Fulda,et al. Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells , 2012, Oncogene.
[31] J. Essigmann,et al. Mechanisms of resistance to cisplatin. , 2001, Mutation research.
[32] Gong Yang,et al. The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer , 2011, Clinical Cancer Research.
[33] Xiaoxin Xu,et al. The role of Bcl-x(L) protein in nucleotide excision repair-facilitated cell protection against cisplatin-induced apoptosis. , 2009, DNA and cell biology.
[34] K. Inoki,et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.
[35] W. Kolch,et al. Raf Kinase Inhibitor Protein Interacts with NF-κB-Inducing Kinase and TAK1 and Inhibits NF-κB Activation , 2001, Molecular and Cellular Biology.
[36] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[37] J. Graff,et al. eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.
[38] K. Yeung,et al. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. , 2009, Cancer research.
[39] Serge Eifes,et al. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. , 2008, Biochemical pharmacology.
[40] S. Badve,et al. NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 , 2007, Oncogene.
[41] B. Aggarwal,et al. RKIP Sensitizes Prostate and Breast Cancer Cells to Drug-induced Apoptosis* , 2004, Journal of Biological Chemistry.
[42] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[43] C. Trautwein,et al. NFκB Mediates Apoptosis through Transcriptional Activation of Fas (CD95) in Adenoviral Hepatitis* , 2000, The Journal of Biological Chemistry.
[44] R. Perona,et al. Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. , 2002, Molecular biology of the cell.
[45] R. Turner,et al. X-Linked Inhibitor of Apoptosis Protein Expression Level in Colorectal Cancer Is Regulated by Hepatocyte Growth Factor/C-Met Pathway via Akt Signaling , 2005, Clinical Cancer Research.
[46] A. Hoffmann,et al. CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. , 2003, Molecular cell.
[47] C. Gélinas,et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB , 2001, Nature Cell Biology.
[48] K. Vousden,et al. Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.
[49] H. Walczak,et al. Identification of PP2A as a crucial regulator of the NF-κB feedback loop: its inhibition by UVB turns NF-κB into a pro-apoptotic factor , 2008, Cell Death and Differentiation.
[50] Peter Scheurich,et al. NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling , 2001, Molecular and Cellular Biology.
[51] P. Yeh,et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. , 2002, Biochemical pharmacology.
[52] G. Evan,et al. Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.
[53] J. Bromberg. Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.
[54] B. Tsang,et al. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro , 2004, Oncogene.
[55] N. Perkins,et al. Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB , 2004 .
[56] Hongtao Yu,et al. Short hairpin RNA targeting c-FLIP sensitizes human cervical adenocarcinoma Hela cells to chemotherapy and radiotherapy. , 2008, Cancer letters.
[57] S. Hong,et al. Proapoptotic effects of NF-κB on cisplatin-induced cell death in auditory cell line , 2008, Acta oto-laryngologica.
[58] S. Gibson. Epidermal growth factor and trail interactions in epithelial-derived cells. , 2004, Vitamins and hormones.
[59] E. Solary,et al. Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs* , 1999, The Journal of Biological Chemistry.
[60] C. Chao,et al. Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling. , 2003, The Biochemical journal.
[61] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[62] W. Xiao. The mitochondrial pathways of apoptosis , 2002 .
[63] William Arbuthnot Sir Lane,et al. NF-κB2 p100 is a pro-apoptotic protein with anti-oncogenic function , 2002, Nature Cell Biology.
[64] D. Guertin,et al. The Pharmacology of mTOR Inhibition , 2009, Science Signaling.
[65] Carol L. Williams,et al. SmgGDS Regulates Cell Proliferation, Migration, and NF-κB Transcriptional Activity in Non-small Cell Lung Carcinoma* , 2008, Journal of Biological Chemistry.
[66] P. Hanawalt,et al. DNA repair: from molecular mechanism to human disease. , 2006, DNA repair.
[67] Douglas B. Evans,et al. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. , 2004, Journal of Biological Chemistry.
[68] J. Gregg,et al. Rapamycin Inhibits Growth of Premalignant and Malignant Mammary Lesions in a Mouse Model of Ductal Carcinoma In situ , 2006, Clinical Cancer Research.
[69] P. Chiao,et al. Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response. , 2005, The Journal of biological chemistry.
[70] M. Toi,et al. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.
[71] Marty W. Mayo,et al. NF-k B Antiapoptosis : Induction of TRAF 1 and TRAF 2 and c-IAP 1 and c-IAP 2 to Suppress Caspase-8 Activation , 1998 .
[72] K. Umezawa,et al. Molecular design and biological activities of NF-kappaB inhibitors. , 2002, Molecules and cells.
[73] A. Khwaja,et al. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.
[74] H. Pahl,et al. Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.
[75] M. Tarpin,et al. In vitro and in vivo anti‐tumoral effect of curcumin against melanoma cells , 2004, International journal of cancer.
[76] S. Byun,et al. The role of c-FLIP in cisplatin resistance of human bladder cancer cells. , 2013, The Journal of urology.
[77] Mutsushi Yamasaki,et al. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. , 2005, Oncology Report.
[78] K. Umezawa. Inhibition of tumor growth by NF‐κB inhibitors , 2006 .
[79] J. Cohen,et al. Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells , 2007, Journal of Virology.
[80] S. Radhakrishnan,et al. Pro-apoptotic role of NF-κB: Implications for cancer therapy , 2006 .
[81] V. Zinzalla,et al. Activation of mTORC2 by Association with the Ribosome , 2011, Cell.
[82] Z. Hall. Cancer , 1906, The Hospital.
[83] T. Wilson,et al. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells , 2008, Molecular Cancer Therapeutics.
[84] Susanne J. Braeuer,et al. Constitutively Activated Nuclear Factor-κB, but not Induced NF-κB, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells , 2006, Molecular Cancer Research.
[85] B. Tsang,et al. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. , 2008, Cancer research.
[86] Gang Li,et al. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. , 2001, Experimental cell research.
[87] NFκB Mediates Apoptosis through Transcriptional Activation of Fas (CD95) in Adenoviral Hepatitis* , 2000, The Journal of Biological Chemistry.
[88] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[89] Ruili Huang,et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. , 2010, Biochemical pharmacology.
[90] W. Kolch,et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP , 1999, Nature.
[91] Paolo Sassone-Corsi,et al. Bindarit: an anti-inflammatory small molecule that modulates the NFκB pathway. , 2012, Cell cycle.
[92] G. Pond,et al. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia , 2006, Investigational New Drugs.
[93] Ivan Babic,et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. , 2011, Cancer discovery.
[94] R. Perng,et al. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. , 2000, Journal of biomedical science.
[95] G. Stark,et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.
[96] M J May,et al. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.
[97] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[98] A. Hoffmann,et al. CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response , 2003 .
[99] W. Kolch,et al. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. , 2001, Molecular and cellular biology.
[100] D. Vaux,et al. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[101] P. Chiao,et al. Function of Polo-like Kinase 3 in NF-κB-mediated Proapoptotic Response* , 2005, Journal of Biological Chemistry.
[102] D. Trisciuoglio,et al. relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells , 2001, British Journal of Cancer.
[103] Malay Mandal,et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. , 2007, Nature medicine.
[104] Wendy L. Allen,et al. Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells , 2007, Molecular Cancer Therapeutics.
[105] J. Shah,et al. A phase 2 study of bevacizumab with cisplatin plus intensity‐modulated radiation therapy for stage III/IVB head and neck squamous cell cancer , 2012, Cancer.
[106] J. Kigawa,et al. Activation of the Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Overcomes Cisplatin Resistance in Ovarian Carcinoma Cells , 2012, International Journal of Gynecologic Cancer.
[107] G. Sledge,et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. , 2000, Oncogene.
[108] Malay Mandal,et al. Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia , 2007, Nature Medicine.
[109] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[110] W L Allen,et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death , 2006, Oncogene.
[111] S. Ghosh,et al. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. , 2005, Arthritis and rheumatism.
[112] K. Umezawa. Inhibition of tumor growth by NF-kappaB inhibitors. , 2006, Cancer science.
[113] V. Dixit,et al. Death receptors: signaling and modulation. , 1998, Science.
[114] D. Jeoung,et al. CAGE, a cancer/testis antigen, induces c-FLIPL and Snail to enhance cell motility and increase resistance to an anti-cancer drug , 2009, Biotechnology Letters.
[115] Razelle Kurzrock,et al. Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer , 2008, Clinical Cancer Research.
[116] S. Radhakrishnan,et al. Pro-apoptotic role of NF-kappaB: implications for cancer therapy. , 2006, Biochimica et biophysica acta.
[117] C. Y. Wang,et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.
[118] Daniel Normolle,et al. Dose escalation of a curcuminoid formulation , 2006, BMC complementary and alternative medicine.
[119] Sang-Gu Hwang,et al. p38 Kinase Regulates Nitric Oxide-induced Apoptosis of Articular Chondrocytes by Accumulating p53 via NFκB-dependent Transcription and Stabilization by Serine 15 Phosphorylation* , 2002, The Journal of Biological Chemistry.
[120] J. Yu,et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.
[121] N. Magné,et al. Activation of Nuclear Factor κB through the IKK Complex by the Topoisomerase Poisons SN38 and Doxorubicin: A Brake to Apoptosis in HeLa Human Carcinoma Cells , 2001 .
[122] Y. Tao,et al. NF-κB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type , 1999, Cell Death and Differentiation.
[123] B. Kamińska,et al. Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity. , 2013, Experimental cell research.
[124] P. Ascierto,et al. NEMO-binding domain peptide inhibits proliferation of human melanoma cells. , 2009, Cancer letters.
[125] G. Peters,et al. A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[126] Ido Amit,et al. Regulation of MAPKs by growth factors and receptor tyrosine kinases. , 2007, Biochimica et biophysica acta.
[127] Y. Ben-Neriah,et al. NF-kappaB inhibition: a double-edged sword in cancer? , 2006, European journal of cancer.
[128] Marty W. Mayo,et al. NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis , 1999, Molecular and Cellular Biology.
[129] Robert E. Brown,et al. Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications. , 2006, Annals of clinical and laboratory science.
[130] Masakazu Toi,et al. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.
[131] S. Gibson,et al. The Two Faces of NF?B in Cell Survival Responses , 2005, Cell cycle.
[132] A. Guglielmotti,et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models , 2012, Clinical & Experimental Metastasis.
[133] J. Darnell. Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.
[134] Ze-Guang Han,et al. XIAP Is a Predictor of Cisplatin-Based Chemotherapy Response and Prognosis for Patients with Advanced Head and Neck Cancer , 2012, PloS one.
[135] J. Seong,et al. Anti-Cancer Activity of a Novel Small Molecule Compound That Simultaneously Activates p53 and Inhibits NF-κB Signaling , 2012, PloS one.
[136] Y. Kaneda,et al. TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. , 2003, Cell death and differentiation.
[137] G. Sledge,et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.
[138] F. Thévenod,et al. Up-regulation of Multidrug Resistance P-glycoprotein via Nuclear Factor-κB Activation Protects Kidney Proximal Tubule Cells from Cadmium- and Reactive Oxygen Species-induced Apoptosis* , 2000, The Journal of Biological Chemistry.
[139] J. Inoue,et al. Inhibition of Tumor Necrosis Factor-α-induced Nuclear Translocation and Activation of NF-κB by Dehydroxymethylepoxyquinomicin* , 2002, The Journal of Biological Chemistry.
[140] R. Pazdur,et al. United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy , 2006, Clinical Cancer Research.
[141] G. Mills,et al. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. , 2010, Cancer research.
[142] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[143] G. Cohen,et al. DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes. , 1996, Molecular pharmacology.
[144] J. Schmid,et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[145] M. Cancro,et al. Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands. , 2005, Seminars in immunology.
[146] J. Inoue,et al. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. , 2002, The Journal of biological chemistry.
[147] Ann Richmond,et al. Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition , 2004, Cancer Research.
[148] S. Steinberg,et al. Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer , 2010, Cancer.
[149] M. Karin,et al. Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. , 2011, Cancer discovery.